EpiBiologics closed a $107 million Series B to advance its EpiTAC protein-degrading antibody platform into human testing, with GV and Johnson & Johnson’s venture arm leading the round. The Bay Area startup plans first-in-human trials for EPI-326, a bispecific designed to degrade oncogenic EGFR on tumor cells while sparing healthy tissue, with dosing planned for H1 2026. Company leadership emphasized that EPI-326’s mechanism—targeted lysosomal degradation of cell-surface proteins—may combine well with existing therapies and improve safety. The financing will also support discovery of additional degrader programs and combination strategies. Prominent strategic backers, including major pharma venture arms, signaled industry interest in extracellular targeted protein degradation. The round highlights continued investor appetite for targeted degradation approaches that expand beyond intracellular E3 ligase recruiters, particularly for solid tumors where selectivity and tolerability are key challenges.